Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy, Biologic therapy.

University of Vermont Cancer Center, Burlington, VT, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Burlington, VT
Treatments:Chemotherapy, Biologic therapyHospital:University of Vermont Cancer Center
Drugs:Journal:Link
Date:Jul 2012

Description:

Patients:
This phase 2 study involved 46 previously treated patients with resistant or refractory ovarian cancer. The median patient age was 64 years.

Treatment:
Patients were treated with the chemotherapy agent called pegylated liposomal doxorubicin and the biologic therapy agent bevacizumab.

Toxicities:
The most severe toxicities were grade 4 headache and neurologic complications. Grade 3 hand-foot skin reaction and increased blood pressure were also reported.

Results:
The median overall survival was 33.2 months.

Support:
This study was supported by the pharmaceutical company Genentech.

Correspondence: Dr. C. F. Verschraegen; email: claire.verschraegen@vtmednet.org



Back